Spain leads Europe in clinical trials, with over 930 authorized studies in 2024 and recruitment rates up to 40% faster than the European average in oncology. However, the European healthcare sector faces critical challenges. Data fragmentation, patient recruitment bottlenecks, and regulatory complexity threaten global competitiveness. Between 2018 and 2023, approximately 60,000 fewer European patients gained access to experimental treatments because of these inefficiencies.
